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Experimental therapyNeuronal ceroid lipofuscinoses are a group of fatal progressive neurodegenerative diseases predominantly af-
fecting children. Identiﬁcation of mutations that cause neuronal ceroid lipofuscinosis, and subsequent func-
tional and pathological studies of the affected genes, underpins efforts to investigate disease mechanisms
and identify and test potential therapeutic strategies. These functional studies and pre-clinical trials necessi-
tate the use of model organisms in addition to cell and tissue culture models as they enable the study of pro-
tein function within a complex organ such as the brain and the testing of therapies on a whole organism. To
this end, a large number of disease models and genetic tools have been identiﬁed or created in a variety of
model organisms. In this review, we will discuss the ethical issues associated with experiments using
model organisms, the factors underlying the choice of model organism, the disease models and genetic
tools available, and the contributions of those disease models and tools to neuronal ceroid lipofuscinosis re-
search. This article is part of a Special Issue entitled: The Neuronal Ceroid Lipofuscinoses or Batten Disease.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
The study of disease mechanisms and the development and testing
of therapeutic strategies for the neuronal ceroid lipofuscinoses (NCLs)
presents signiﬁcant challenges: the use of model organisms is key to
achieving these goals. This group of clinically related storage disorders
predominantly affects children, causing a progressive neurodegene-
ration causing dementia, epilepsy, blindness and motor dysfunction
leading to premature death. Indeed, although individually rare, the
NCLs are the most common cause of childhood neurodegeneration
and dementia with an incidence between 1:12,500 and 1:100,000
(depending on the country) [1] and therefore they pose a signiﬁcant so-
cial and economic burden on families, the health service and the state.
Details of the disease in humans are discussed in detail in other publica-
tions in this special edition. NCL is deﬁned by the progressive accumula-
tion of lysosomal aggregates together with the dysfunction and death of
speciﬁc populations of neurons within the central nervous system. The
identiﬁcation of distinct NCL disease-causing mutations [2] has enabled
studies into protein function, and pathomechanisms, as well as the iden-
tiﬁcation of therapeutic targets and compounds thatmodulate those tar-
gets, and facilitated progress towards the systematic testing of potentialronal Ceroid Lipofuscinoses or
+44 2074685204.
l rights reserved.therapeutic compounds including the ability to use therapeutic strate-
gies based on gene, protein and stem cell transfer. These new studies
have required the use of model organisms, as cell and tissue culture sys-
tems cannot replicate the complexity of the central nervous system or
indicate how a whole organism may respond to an experimental thera-
py.Most importantly, experimental colonies can provide sufﬁcient num-
bers for statistical analysis to support a robust conclusion.
To move towards these goals, it is necessary to identify or generate
organisms that model each form of NCL. In addition, expressing human
genes in model organisms has enabled identiﬁcation of their functions
and interacting partners. A range of organisms and mutations is now
available and more are in development. In this review, in addition to a
summary of organisms with mutations in NCL genes, we present the
other strains of model organisms available for systematic research, and
highlight the most recent and important studies on NCL that employed
the use ofmodel organisms. Each animal has its own distinct advantages
and limitations for experimental studies. Organisms used to date range
from single celled yeast, to invertebrates such as the fruit ﬂy and nema-
tode, through to small vertebrates such as the zebraﬁsh andmouse, and
large vertebrates such as dogs, sheep and cattle, each of which has
orthologues of at least two CLN genes (reviewed in [3]).
In this review we will discuss each species that has made a signif-
icant contribution to NCL research since the last review in this journal
[4] and the recent book [5]. As there is no recent data utilising the
nematode, this organism is not included. For the organisms presented
we summarise their advantages and their use in modelling NCL, un-
derstanding NCL biology and experimental therapeutic testing. We
1843M. Bond et al. / Biochimica et Biophysica Acta 1832 (2013) 1842–1865will also highlight common hypotheses about NCL neuropathogenesis
that have arisen from the study of these model organisms.2. Ethical considerations
Research relating to rare and fatal inherited diseases of children and
the development and evaluation of therapeutic approaches for such dis-
eases creates numerous ethical dilemmas for patients, their families,
health professionals, researchers and regulatory bodies. In the speciﬁc
context of animal models for such diseases ethical considerations relate
largely to two themes: ﬁrstly, themoral status of animals and hence the
acceptability of using animals in research that is of only limited or no
beneﬁt for the animals themselves, and secondly, the validity of animals
as models for human disease. However, it is important to note that the
large animal models of the NCLs have been caused by naturally occur-
ring mutations, were diagnosed by veterinarians concerned with the
disease in these species, and especially in dogs and cattle the character-
isation of the genetic defect resulted in DNA diagnostics that allow
effective management via controlled breeding programmes. Thus, re-
search on these models has at least initially been primarily concerned
with animal welfare. As with many ethical dilemmas, the co-existence
of well informed divergent views, which are based on different philo-
sophical, cultural, social and/or religious frameworks results in a contin-
uum of views in relation to both the moral status of animals [6–8] and
the validity of animal models [7,9,10]. Only respectful, considerate and
open-minded discussion among all stakeholders can lead to acceptable
solutions and the role of researchers in such ‘shared moral reﬂection’
[11] is crucial. Researchers who are using animal models for NCL are
aware of these issues and reﬂect and engage publically in the ethical
discourse [12–14].
A detailed discussion of the moral status of animals is beyond the
scope of this paper, but it should be acknowledged that the moderate
utilitarian approach that underpins legislation relating to animal re-
search inmany countries considers that animals have somemoral status
and accepts a balancing of the costs to one moral agent versus beneﬁts
to anothermoral agent. Under this framework the use of animalmodels
can be morally justiﬁed with an implicit need to minimise suffering in
animals and to prove adequate beneﬁts of research [7,15–17].
Similarly, amore comprehensive review on the debate about the va-
lidity of animal models is attempted elsewhere [14]. However, in the
context of this paper one might ask which species is the best or most
valid model for NCL and how knowledge gained from these models is
translated to the human context. Unfortunately, there is no one species
that is the bestmodel for all the various biomedical questionswe are in-
vestigating. A species that is biologically most similar to humans ap-
pears often attractive but on technical and ethical grounds may not
always be the most practical model [18,19]. The use of multiple animal
species as models in NCL research allows for synergistic outcomes and
cross-validation of researchﬁndings. For example, in relation to preclin-
ical trials for therapeutic approaches for inherited diseases there is an
increased awareness that both small and large animals are required
[20,21].
Care needs to be taken as to what conclusions for human disease
can be drawn from animal models. It needs to be clear that a model
is a model and thus a simpliﬁcation and/or analogue of disease in
humans — and disease in humans is complex. This notwithstanding,
as discussed in this paper, knowledge gained in NCL animal models
has in the past been transferable to the human context and has
been essential in advancing our understanding of genetics, biochem-
istry and pathomechanism and is crucial in the preclinical evaluation
of therapeutic approaches. For rare inherited diseases that affect chil-
dren, such as NCL, clinical trial design is often impacted by important
ethical constraints to minimise harm to vulnerable research partici-
pants [22], in these situations thorough evaluation of therapeutic in-
terventions by a range of animal models appears to be essential.3. Large animals
The use of non-laboratory or large animal models for NCL has re-
cently been extensively reviewed [23]. Since the report of ‘lipid dystro-
phic changes’ in two English setter dogs [24] an extensive literature has
arisen reporting conﬁrmed and suspected naturally occurring cases of
NCL in a large variety of species including other dog breeds (Table 2),
sheep, cattle, ferrets, cats, horses, goats, pigs, birds, monkeys (Table 1)
andmice (Table 3). Identiﬁcation of NCLs in animals is signiﬁcant to en-
able veterinarians to diagnose the disease and provide a prognosis to
patient owners as well as to allow researchers to develop diagnostic
tests for the management of these disorders at a breed level. More
importantly, animals can be indispensable in gaining knowledge of
the analogous human diseases. The studies by Nils Koppang of English
setters [25,26] affected by the disease were a central stimulus for the
ﬁrst international NCL conference, the ‘International Symposium on
Human and Animal Models of Ceroid-lipofuscinosis’ in 1980 [27]. The
ovine CLN6 model quickly followed [28] but it was not until the 1990s
that murine models started to become available. More recently, there
is increased awareness for the need to utilise large animal models in
addition to laboratory animals [20,21,23]. Large animals are more
similar to humans in relation to size (including brain size and struc-
ture), lifespan (Table 1), physiology and clinical signs of NCL disease
(Table 1) and are therefore considered essential in relation to investiga-
tions of complex pathomechanisms and preclinical trials for new thera-
peutic approaches.
Research relating to NCL in large animals reﬂects these purposes.
For many non-laboratory species the literature has described clini-
cal signs and post mortem pathology investigations of individual
or familial cases of animals affected by NCL, for some breeds the
disease causing gene and mutations have been identiﬁed, and ex-
perimental populations of sheep and dogs affected by NCL are
maintained to increase our understanding of the underlying disease
pathomechanism or to evaluate therapeutic approaches (Tables 1
and 2).
3.1. Ovine
Previous literature has described in detail how the ovine exper-
imental NCL populations have increased our knowledge about
NCL [23,29–31]. Most inﬂuential has been the extensive research
on the South Hampshire CLN6 model [28] spanning over three
decades of work. Experimental ﬂocks for a genetically different
Merino CLN6 model [30,32] and a Borderdale CLN5 model [31,33]
have been more recently established. A congenital CLN10/CTSD
Swedish Landrace model [29,34] is no longer available as a research
population.
3.1.1. Past research in ovine models identiﬁed key aspects of disease
mechanism, provided leads for therapeutic approaches and insights into
genetics
Research in ovine models for NCL has been essential to increase
our understanding of the complex disease mechanism and is here
only brieﬂy summarised. Early research in the South Hampshire CLN6
model [35–42] did not support previous hypothesis of pathogenesis,
i.e. the idea that the disease mechanism was related to dysfunction of
the regulation of peroxidation of lipids [43–46] and the hypothesis of
a defect in retinoic acid catabolism [47]. The identiﬁcation and charac-
terisation of subunit c of mitochondrial ATP synthase as the major pro-
tein storage component in South Hampshire sheep [36,41,48–52] led
subsequently to the important recognition that subunit c of mitochon-
drial ATP synthase is the main storage component for the majority of
NCL variants in humans and animals (Table 1) [5,50]. Furthermore,
studies in South Hampshire sheep identiﬁed that excitotoxicity was
not causative in relation to neurodegeneration as previously suggested
Table 1
Summary of large animal models with conﬁrmed or suggested NCL (dogs not included).
Clinical signs cd Storage material cdSpecies/breed(Life spana)
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Sheep (20)
South 
Hampshire
CLN6 deletion of  
exon 1
Lack of 
protein
7 − 12 m Yes 25 −
30 m
Yes Yes Yes Yes Yes Lamellar SCMAS General [28, 30, 64, 94]
Swedish 
Landrace
CTSD/CLN
10
Gb>A Aspb>Asn
non-
functional 
protein
at birth Yes < 1 m nd Yes Yes Yes Yes GRODs SAPs General [29, 34]
Merino CLN6 c.184C>T p.Arg62Cys
non-
functional 
protein
7 m Yes 19 −
27 m
Yes Yes Yes Yes Yes Lamellar SCMAS General [30, 32, 95]
Borderdale CLN5 c.571+1G>A Splicing 
variant, 
truncated 
protein
10 − 11 m Yes 24 m Yes Yes nd nd Yes Lamellar SCMAS General [31, 33] D.N. Palmer 
personal communication
Rambouillet n.d. 8 m Yes 24 m Yes Yes Yes nd Yes nd nd Neuronal [96-98]
Cattle (20)
Devon CLN5 c.662dupG p.Arg221Glyf
sX6
truncated 
protein
9 m Yes 39 m Yes Yes Yes no Yes Lamellar SCMAS General [99-101]
Beefmaster 12 m nd 18 m Yes Yes nd Yes nd Lamellar nd General [102]
Holstein nd Yes 18 m Yes nd nd nd Yes Lamellar nd General [103]
Ferret (12)
Domestic > 3 y Yes nd Yes Yes Yes nd Yes Lamellar SCMAS General [104] M. France 
personal communication
Domestic 3 m nd 4 m nd Yes Yes nd Yes GRODs SAPs General [92]
Cat (34)
Domestic short-haired 8.5 m nd 9 m Yes nd Yes Yes Yes Lamellar SCMAS Neuronal [105]
Siamese < 22 m nd 23 m Yes Yes Yes Yes nd Lamellar nd General [106]
Domestic short-haired 15 m Yes 20 m Yes Yes no Yes Yes Lamellar nd Neuronal [107]
Japanese 7 m nd 11 m nd nd Yes Yes Yes GRODs nd General [108]
Horse (50)
Aegidienberger 6 m nd 24 m Yes Yes Yes nd Yes Lamellar SCMAS General [109]
Goat (20)
Nubian 10 − 18 m nd 2 − 4 y nd Yes Yes nd Yes Lamellar nd Neuronale [110]
Pig (20)
Vietnamese 
pot−bellied
2 y  nd 2.5 y no no Yes no Yes Lamellar 
GRODs
nd Neuronal [111]
Parrot 
Lovebird (12) < 9 m
1 y
nd
nd
9 m
3 y
nd nd Yes Yes Yes
Yes Yes Yes Yes Yes
nd nd Neuronal [112]
Monkey 
Cynomolgus monkey 
(37)
Preclinical at 7 y Yes variable nd General [113]
Duck (29)
Mallet duck nd nd Neuronal [93]
Grey Active experimental populations are shaded in grey, nd=not reported, SAPs=sphingolipid activator proteins, SCMAS=subunit C of mitochondrial ATP synthase.
aMaximum life span in years (http://www.demogr.mpg.de/cgi-bin/longevityrecords/entry.plx/).
bCorresponding to G934 and Asp295 of corresponding human CTSD sequence.
cVI=visual impairment, BC=behavioural changes, MD=motor deﬁcits, S=seizures.
dF=ﬂuorescent, US=ultrastructure, D=distribution.
eOnly central nervous system investigated.
1844 M. Bond et al. / Biochimica et Biophysica Acta 1832 (2013) 1842–1865[53] and that instead observed changes in interneuron populations
followed pathogenesis [54,55].
The importance of the role of neuroinﬂammation in NCL prior to
neurodegeneration was ﬁrst identiﬁed in time course studies on dis-
ease progression in South Hampshire sheep [56,57] and has led to
the investigation of anti-inﬂammatory drugs as new therapeutic ap-
proaches in affected South Hampshire sheep (D. N. Palmer, personal
communication) and other species.Previously, affected South Hampshire sheep have been useful in
the evaluation of bone marrow transplantation [58] and more recent
work in relation to gene therapy is described below.
The identiﬁcation of CLN6 and CLN5 as causative genes in the South
Hampshire, Merino and Borderdale sheep supported previous ﬁndings
that these genes caused disease in humans. More importantly, the iden-
tiﬁcation of CTSD as the disease causing gene inWhite Swedish Landrace
sheep [29]was theﬁrst report of an NCL caused by amutation in amajor
Table 2
Summary of canine models with conﬁrmed or suggested NCL.
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Confirmed NCL
Miniature dachshund PPT1/CLN1 c.736_73
7insC
Frameshift 
after Gly245 
with stop 
codon at 
position 276
9 mo Yes nd Yes Yes Yes No Yes GRODs nd Neuronal [114]
Longhaired 
Dachshund
TPP1/CLN2 c.325delC Frame shift 
after amino 
acid 107 (exon 
4) with stop 
codon at 
position 114
7 - 9 mo Yes 12 mo Yes Yes Yes Yes Yes Lamellar nd Neuronal [85, 88, 115, 116]
Border collie CLN5 c.619C>T Truncated 
protein (stop 
codon Q206X)
16 -
23 mo
Yes 28 mo Yes Yes Yes Yes Yes Lamellar nd Neuronal [117-121]
Australian shepherd CLN6 c.829T>C Missense 
Trp277Arg
1 - 2 y Yes nd Yes Yes Yes nd Yes Lamellar nd Neuronal [122, 123]
English setter CLN8 c.491T>C Missense 
L164P
1 - 2 y Yes 2 y Yes Yes Yes Yes Yes Lamellar SCMAS Neuronal [124-142]
American bulldog CTSD/CLN
10
c.?G>A Missense 
Met199Ile
1 - 3 y no 7 y no Yes Yes no Yes Round 
uniformly 
staining 
inclusions 
embedded
within 
granular 
matrixes
nd Neuronal [143-145]
Tibetan terrier ATP13A2/
CLN12
1620delG Skipping of 
exon 16 
leading to 
shortened 
protein
5 - 7 y Yes nd Yes Yes Yes Yes Yes Lamellar; 
granular 
contents
nd Neuronal [78, 79, 146-149]
American 
Staffordshire (Pit Bull) 
Terrier
ARSG 296G>A Missense 
Arg299His
3 - 5 y no nd no no Yes no nd Lamellar nd Neuronal [83, 150]
Australian shepherd 
(not CLN6)
nd nd nd 15 mo Yes nd Yes Yes Yes nd Yes Lamellar nd Neuronal [122]
Polish owczarek 
Nizinny/Polish 
Lowland sheepdog
nd nd nd 6m - 4y Yes 8 y Yes Yes Yes no Yes GRODs SAPs General [137, 151-153]
Miniature schnauzer nd nd nd 2 y Yes nd Yes Yes Yes no Yes GRODs SAPs Neuronal [154-157]
Chihuahua nd nd nd 16 -
18 mo
Yes 24 mo Yes Yes Yes no Yes Lamellar nd General [158, 159]
Cocker spaniel nd nd nd 18 mo Yes 6 y Yes Yes Yes Yes Yes Lamellar nd Neuronal 
and 
General
[160-162]
Dalmatian nd nd nd 6 mo Yes 6 yr Yes Yes Yes Yes Yes Lamellar nd General [163, 164]
Japanese retriever nd nd nd 3 y nd nd nd nd nd Yes Yes nd nd General [165]
Welsh corgi nd nd nd 6 - 8 yr Yes nd Yes Yes nd Yes nd nd nd nd [166]
Labrador retriever nd nd nd 7 y no nd no no Yes Yes nd Lamellar nd Neuronal [167]
Australian cattle dog nd nd nd 1 y Yes Yes no Yes no [168, 169]
Saluki nd nd nd 1 y no 2 y no Yes Yes no Yes Lamellar nd Neuronal [170]
Grey Active experimental populations are shaded in grey, nd=not reported, SAPs=sphingolipid activator proteins, SCMAS=subunit C of mitochondrial ATP synthase.
aVI=visual impairment, BC=behavioural changes, MD=motor deﬁcits, S=seizures.
bF=ﬂuorescent, US=ultrastructure, D=distribution.
cOnly central nervous system investigated.
1845M. Bond et al. / Biochimica et Biophysica Acta 1832 (2013) 1842–1865lysosomal protease and the ﬁrst study of an NCL animal model that has
led to the identiﬁcation of a new candidate gene for a human NCL [59].
Finally, CLN5 and CLN6 sheep models have allowed for the sys-
tematic generation of research resources such as RNA, DNA and tissue
samples as well as neuronal cell cultures that have, in addition to
similar material from laboratory animals, assisted in basic researchrelating to normal and abnormal function of NCL genes and proteins
(e.g. [60–63]).
3.1.2. Current research
Since the last review [23] research relating to experimental NCL
populations in South Hampshire, Merino and Borderdale sheep was
1846 M. Bond et al. / Biochimica et Biophysica Acta 1832 (2013) 1842–1865recently presented at the 13th International Conference on Neuronal
Ceroid Lipofuscinoses (http://www.ncl2012.org/). Firstly, a large de-
letion that includes exon 1 of the CLN6 gene has been identiﬁed as
the disease causing mutation in the South Hampshire model [64],
conﬁrming previous genetic research that proposed South Hampshire
sheep as a model for CLN6 disease [30]. Secondly, research using this
South Hampshire model in relation to pathogenesis explored the role
of cytokines in neuroinﬂammation [65] and the role of alterations in
metal homeostasis and cellular signalling pathways in the brain of af-
fected sheep [66]. Furthermore, primary sheep neuronal cells were
used in a study of early changes to lysosomes and the endoplasmic
reticulum with the aim to develop a better understanding of early pa-
thology which could assist in the development of in vitro tests for the
evaluation of current gene therapy trials in these sheep [67].
Finally, progress has beenmade in relation to using sheepmodels to
develop or evaluate therapeutic approaches. Longitudinal biomarkers of
disease progression, including behaviour studies, computer tomogra-
phy andmagnetic resonance imaging, are developed for all three exper-
imental sheep populations [68–70]. The potential role of neuronal
progenitor cells and neurogenesis as natural attempts of brain repair
is investigated. Evidence of increased neurogenesis in the subven-
tricular zone and possible clusters of newly generated neurons in the
cortex was found in the CLN6 South Hampshire sheep, in the CLN5
Borderdale model and in human CLN6 patients but these cell clusters
in the cortexwere absent in the CLN6mousemodel [71,72]. Thisﬁnding
strengthens our argument that the use of a diversity of animal models
and especially large animal models with brains and pathology more
similar to humans is important and further research is required to iden-
tify how this phenomenon can be useful for therapeutic approaches.
Chimeric sheep generated from CLN6-affected and normal embryos
have been investigated to explore the ability of in vivo intercellular
correction for NCL caused bymembrane proteins [73]. Initial promising
ﬁndings suggest that intercellular correction is not impossible, as
previously believed, thus creating new opportunities for therapeutic
interventions such as gene therapy or stem cell therapy. Preliminary
ﬁndings in a study that evaluated the calpain inhibitor (CAT0811) as
an anti-neurodegenerative therapeutic agent in CLN5 Borderdale sheep
were presented [69]. Most importantly, previous investigations into
lentiviral mediated gene transfer with the aim to develop gene therapy
for NCL [74] have progressed. Further work on the generation and test-
ing of lentiviral vectors for CLN5 and CLN6 and tests on transgene ex-
pression and function in vivo in a large human-like brain and in vitro
were presented [70,75].
3.1.3. Summary
Extensive and systematic research in four well characterised ovine
models of NCL for more than three decades provided key insights in
the disease mechanisms and informed development and evaluation of
new therapeutic approaches. Most importantly, early misconceptions
with regard to disease mechanism could be rejected based on ovine
research and the ﬁndings that subunit c of mitochondrial ATP synthase
is the major protein storage component in most variants of NCL and
that neuroinﬂammation plays an important role in pathogenesis shifted
our understanding of the disease mechanisms and informed the devel-
opment of new therapeutic approaches. A new candidate gene for NCL –
CTSD – was proposed and conﬁrmed as disease causing in humans. In
the future, the existence of these well characterised and easy to main-
tain ovine research ﬂocks will be vital to further unravel the poorly un-
derstood disease mechanism and to continue the development and
evaluation of therapeutic approaches.
3.2. Canine
There is a wealth of literature describing the clinical and pathologi-
cal consequences of mutations in NCL genes in various dog breeds
(see the references in Table 2 and [76]), providing important criteriafor diagnosis and for the monitoring of experimental therapy testing.
To date, studies on NCL in dogs have signiﬁcantly advanced the reper-
toire of genes that are known to cause NCL when mutated, provided
mechanistic insights and enabled the testing of experimental therapies
in a relatively large brain.
3.2.1. Identiﬁcation of candidate NCL genes also provides mechanistic
insights
Diagnostic tests are available for many dog breeds and are being
used widely to reduce breeding of carrier dogs. Since the last review
and the ﬁrst high quality build of the canine genome in July 2004
[77], the causative mutations in 8 breeds have been found (Miniature
Dachshund, Longhaired Dachshund, Border Collie, Australian Shep-
herd, English Setter, American Bulldog, Tibetan Terrier and American
Staffordshire Terrier; Table 2). Most signiﬁcantly, one naturally occur-
ring model has demonstrated that novel mutations in genes already
known to underlie other neurodegenerative diseases also cause NCL.
The Tibetan Terrier has a mutation in ATP13A2 [78,79], and mutations
in the same gene are also found in a rare form of Parkinson's disease
called Kufor–Rakeb syndrome. As it has been demonstrated that
ATP13A2 is protective against manganese induced toxicity in mamma-
lian cells and yeast [80,81], this already points to a putative disease
mechanismnot previously linked toNCL that requires further investiga-
tion. The identiﬁcation of the mutation in ATP13A2 in Tibetan Terriers
with NCL [78,79] supported the demonstration that a mutation in
ATP13A2 causes CLN12 disease in an NCL-affected family in Belgium
[82]. Similarly, the identiﬁcation of mutations in the canine arylsulfatase
G (ARSG) gene as a cause of NCL in American Staffordshire Terriers [83]
(Fig. 1) provides a novel candidate gene for sequencing in NCL patients
for whom the underlyingmutation is not known. At least eleven breeds
of dogs with NCL still harbour unidentiﬁed mutations but these are ei-
ther old or isolated cases and until new cases are found the underlying
mutation is unlikely to be identiﬁed [76]. However, these breeds still re-
main a potential source of novel NCL genes that will provide candidates
for mutations in humans.
Although examination of NCL in dogs has provided important
mechanistic insights into the disease in the past (reviewed in [76]),
the identiﬁcation and generation of mouse models seem to have
resulted in a reduction in the use of dogs for mechanistic studies.
3.2.2. Development of experimental therapies
The canine NCL models are increasingly being exploited for the
testing of experimental therapies because of several advantages: to
study the effect of the therapy on a larger brain that is more similar
to the human brain than the rodent brain is, to monitor the outcome
of the therapy over a protracted period, and to test the therapy in a
model whose clinical progression resembles that of a human more
closely. Experimental colonies are necessary for the testing of exper-
imental therapies, and colonies of Longhaired Dachshund (CLN2 mu-
tation) and English Setters (CLN8 mutations) exist. Although much of
the work is still unpublished, it was revealed at the 13th International
Conference on Neuronal Ceroid Lipofuscinosis (www.ncl2012.org) that
these dogs are being carefully examined for biomarkers andquantitative
clinical assays for use when assessing the efﬁcacy of experimental ther-
apies [84,85] and the Longhaired Dachshund has been employed to test
a variety of methods for delivery of TPP1 to the canine brain including
intrathecal and intracerebral ventricular administration of recombinant
protein [86–88], and AAV-mediated transduction of brain ependyma
[89]. Importantly, the use of dogs allows the delivery device to be tested
for suitability, as well as indicating the spread and relative expression
levels of TPP1, and the efﬁcacy of the treatment. Based on efﬁcacy in
the canine TPP1 mutant, together with toxicology and pharmacokinetic
data from a variety of species including non-human primates, Biomarin
announced that it is planning a clinical trial for rhTPP1 treatment during
2013. However, studies in mice on the use of combinatorial treatments
to treat CLN1 disease have shown synergistic effects [90,91], suggesting
Fig. 1. Clinical and histopathological features of canine arylsulfatase G deﬁciency. (A) Thewide-based stance (white polygon) of a 5-year-old affected American Staffordshire Terrier (AST)
illustrates loss ofmotor coordination. (B) Sagittal 2-T weightedMRI of the brain from a 6-year-old AST through the cerebellum. (Inset) A similar image at the same scale of the cerebellum
from an age-matched healthy AST, the outline of which has been projected on the cerebellum of the main image (white dotted line). A reduction of grey matter is demonstrated by
the enlarged sulci (arrowheads). (C and D) Transverse sections of the cerebellum from healthy dogs (C) and affected dogs (D) stained with PAS reagent and counterstained in Mayer's
hematoxylin solution. (C) In a normal cerebellum, the large PAS-negative Purkinje neurons lie between the molecular (top left) and granular (bottom right) layers. (D) In the cerebellum
from an affected dog, massive Purkinje cell loss results in a blurry line. The remaining Purkinje neurons (arrows) or neuron remnants (arrowheads) accumulate perinuclear PAS-positive
granular material. (Inset) Affected Purkinje neurons imaged on transmission electron microscopy show accumulated lysosomal material composed of concentric straight or curved pro-
ﬁles with alternating clear and dense bands. (Scale bars: 50 μm for the sections; 250 nm for the inset.)
Reproduced with permission [83].
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compounds should also be trialled in the canine model of CLN2 disease
to see if efﬁcacy can be further improved.3.2.3. Summary
Canine models of NCL have resulted in the identiﬁcation of new
candidate genes for human NCL, provided mechanistic insight into
NCL through the identiﬁcation of novel disease genes and pathologi-
cal examination, and enabled testing of experimental therapies. In
the future, canine NCL models will continue to provide new candidate
genes until the mutations have been identiﬁed in all of those breeds
for which there is suitable tissue available. This will lead to a speciﬁc
diagnosis for more patients and further insights into disease mecha-
nisms. The use of the canine laboratory populations for testing of ex-
perimental therapies will continue to be extremely important, and
the formation of further colonies with mutations in different genes
will provide an important resource for the testing of experimental
therapies for more forms of NCL.3.3. Other large animals
Many other large animal models for NCL exist and are summarised
in Table 1 and in the previous review [76]. Two recent reports of nat-
urally occurring NCLs in non-laboratory species include a new variant
of NCL in a ferret [92] and a duck that was suspected to have NCL [93],
and key ﬁndings are included in Table 1.4. Mouse
Mouse models are an excellent genetic tool to gain insight into the
pathogenesis of neurodegenerative diseases. In the last decade, un-
derstanding of the molecular mechanisms underlying NCL has been
enormously improved due to studies on mice recapitulating the clin-
ical features of this devastating disorder. NCL mouse models have also
proven useful for evaluating the beneﬁts of potential therapeutic
treatments. It is, however, important to bear in mind that the data
obtained needs to be carefully transferred to humans as rodents ex-
hibit less pronounced neuroanatomical structures and a relatively
simple behaviour pattern.
The existing NCL mouse models originate either from naturally oc-
curring mutagenesis or have been developed through biotechnological
modiﬁcations targeting a speciﬁc gene or gene locus tomimic accurate-
ly human genotypic defects (Table 3, genetically accurate models are
highlighted in bold). To facilitate direct comparison, there has been a
concerted effort to establish the same strain backgrounds, C57BL/6,
across the different mouse models. As a result, several mouse strains
are available now that model the major NCL forms of childhood
(Table 3). Collectively, they all show severe brain atrophy and
autoﬂuorescent storage material accumulation. Other mice have been
discovered that display an NCL-like phenotype but as yet these do not
correlate with any known human NCL.
It is evident that research has focused largely on structural or
functional changes in the brain of each mouse model. Therapeutic
achievements have particularly been made in NCL mice expressing
mutant soluble proteins; whereas, the development of possible
Table 3
Summary of mouse models with conﬁrmed or suggested NCL.
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CLN1 
disease, 
infantile
Ppt1—
knockout
Ex. 9 neo 
cassette 
insertion
No enzyme 
activity
< 2 m + + < 5 m + + + + + GROD SCMAS [180] Enzyme replacement therapy [255] 
AAV gene therapy [264, 265] 
AAV gene therapy & bone marrow  
transplantation [266] 
Stem cell transplantation [267] 
Ppt1Δex4
knockout
Ex. 4 deletion No enzyme 
activity
< 4 m + nd 6.5 m + nd + + + nd SAPs [181] nd
CLN2 
disease, late-
infantile
Tpp1 neoins
Arg446His 
knockout
Ex. 11 missense 
mutation & In. 
11 neo cassette 
insertion
No enzyme 
activity
< 9 wk nd nd nd nd + + + + nd nd [193] Enzyme replacement therapy [194,  
257]
AAV gene therapy [260-262] 
CLN5 
disease, 
variant late-
infantile
Cln5-/ -
knockout
Ex. 3 neo 
cassette 
insertion 
Deleted 
mRNA
13 wk < 13 wk + nd + nd nd nd + CLP, 
FPP
nd [195] nd
CLN6 
disease, 
variant late-
infantile 
Cln6nclf 
spontaneous
Single base pair 
insertion 
Frameshift 
after 
Pro102
< 8 m + + 12 m nd nd + nd + CCLP, 
FPP, 
RLP
SCMAS [199] nd
CLN8 
disease, 
variant late 
infantile
Cln8mnd_
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Single base pair 
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Frameshift 
after Val89
< 2 - 3 m + + 10 - 12 m + + + + b + CLP SCMAS [203] AMPA receptor antagonist [272]
Carnitine [271, 273] 
β2-adrenoceptor agonist [274]
CLN3 
disease, 
juvenile
Cln3Δex7/8 
neo 
knockout
Ex. 7-8 neo 
cassette 
insertion
Deleted 
mRNA, 
splicing 
< 14 wk Reduced 
cell density
in retina 
nd nd + + nd nd + CCLP, 
FPP, 
RLP
nd [220] nd
Cln3Δex1-6 
knockout
Ex. 1-6 neo 
cassette 
insertion
Deleted 
mRNA, 
absent 
protein
< 16 m Optic nerve 
degeneration 
<6m [198] 
+ 20 m nd nd + + a + RLP, 
FPP
SCMAS [221] AMPA receptor antagonist [269] 
NMDA receptor antagonist [270] 
Immunosuppression [275] 
Cln3Δex7/8
knock-in
Ex. 7-8 deletion Deleted 
mRNA, 
splicing 
variant
10 - 12 m + + < 7 m + + + nd + FPP SCMAS [222] nd
Cln3lacZ/lacZ
knock-in
LacZ insertion 
& ex 2-8 and 
most of ex. 1 
deletion
β-gal 
expression, 
absent 
CLN3 
protein
< 2 m nd nd nd nd + + + b + nd nd [223] nd
nd=not reported, SAPs=sphingolipid activator proteins, SCMAS=subunit C of mitochondrial ATP synthase, CLP=curvilinear proﬁle, FPP=ﬁngerprint proﬁle, RLP=rectilinear
proﬁle.
aIncreased seizure-induction latency in immature animals aged 35–42 days [285].
bEnhanced susceptibility to drug induced seizures.
cVI=visual impairment, BC=behavioural changes, MD=motor deﬁcits, S=seizures.
dF=ﬂuorescent, US=ultrastructure.
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challenging. The present work summarises the pathologic character-
istics and new therapeutic insights on the current NCL mouse models,
therewith providing an update on the last reviews in this journal in
2006 and 2009 [171,172]. Due to the extensive data, the animal
models are grouped by disease to indicate conserved and variable
phenotypic features. Moreover, candidate NCL mouse models are high-
lighted and recent therapeutic interventions are brieﬂy presented.
4.1. Mouse models of NCL
The cathepsin D (Ctsd) knockout mouse that carries a mutation in
exon 4 of the Ctsd gene similar to humans represents an animal model
for congenital CLN10 disease. In line with the human pathogenesis,thesemice exhibit an aggressive phenotypewith progressive neurolog-
ical symptoms, acute accumulation of autoﬂuorescent storage material
and defects in visceral organs. Death usually occurs at the age of 26±
1 days [173,174]. Brain areas affected early on are the somatosensory
cortex and related thalamic nuclei with profound microglia activation,
astrocytosis, axonal degeneration and neuronal death [175]. The cause
of the cell death is not known; however, it was suggested that glial
cell activation, oxidative stress and autophagy might play a role
[174,176,177]. The removal of the pro-apoptotic protein Baxdid not sig-
niﬁcantly decrease neuronal cell loss supporting further the involve-
ment of non-apoptotic death mechanisms in the neuronal
degeneration of Ctsd−/−mice [178].
Interestingly, morphological and functional alterations of the
presynapse were found before the onset of clinical signs consistent
1849M. Bond et al. / Biochimica et Biophysica Acta 1832 (2013) 1842–1865with recent ﬁndings showing a reduced frequency of mEPSCs (minia-
ture excitatory postsynaptic currents) at early stages of the disease in
Ctsd−/−mice [175,179]. The synapse may, therefore, present a poten-
tial target for early therapeutic intervention.
Two infantile CLN1 disease mouse models exist that lack Ppt1
(palmitoyl protein thioesterase-1) enzyme activity through the tar-
geted disruption of exon 9 (Ppt1−/− knockout) or complete deletion
of exon 4 (Ppt1Δex4 knockout) in the Ppt1 gene [180,181]. Phenotypical-
ly, the two models are similar in that both present with vision loss,
spontaneous seizures and motor abnormalities; the progression, how-
ever, is slightly faster in Ppt1Δex4 knockout mice with death at an age
as early as 5 months [180,181]. A regional selectivity is apparent in
the series of pathogenic events in thesemice. Before the onset of neuro-
logical signs astrocytosis commences in thalamic nuclei and cortical
laminae, spreads extensively and is followed by GABAergic cell loss
and microglia activation in corresponding (sub)cortical regions
[182,183]. A similar progressive pattern is seen in the cerebellum of
Ppt1 deﬁcient mice [181,184].
In line with ﬁndings in Ctsd−/−mice, a synaptic pathology was de-
scribed in these mouse models for infantile CLN1 disease including a
decreased frequency of miniature synaptic currents, reduction in syn-
aptic vesicle pool size, defects in synaptic vesicle recycling and altered
expression of synaptic protein marker [185–187]. Recently, the func-
tion of glutamate receptors was reported to be altered in Ppt1 deﬁ-
cient neurons [188]. Gene expression proﬁles indicated impairment
in neuronal development, calcium homeostasis, lipid metabolism
and trafﬁcking [189]. However, the mechanisms that mediate the
ultimate neuronal loss in these mice remain elusive. Oxidative and
ER (endoplasmic reticulum) stress as well as UPR (unfolded protein
response) and RAGE (receptor for advanced glycation end products)
induction were suggested to play a role in caspase activation and sub-
sequent apoptosis [190–192].
The Tpp1−/− mouse model mirroring late infantile CLN2 disease
was created by a Cln2-speciﬁc missense mutation (equivalent to p.
Arg447His) and a large intronic insertion resulting in the abolishment
of Tpp1 (tripeptidyl peptidase 1) enzyme activity. The mice are char-
acterised by a strongly progressive phenotype with clinical features
apparent from 7 weeks of age onwards including tremors, spon-
taneous seizures and rapid loss of motor function [193]. Prominent
neurodegeneration and glial activation were observed in the thal-
amocortical system and the cerebellum accompanied by widespread
reactive astrocytosis at disease end stage [193,194]. Vision loss, a sig-
niﬁcant symptom of human late infantile CLN2 disease, was not
reported [193].
The insertion of a neomycin cassette into the exon 3 of the murine
Cln5 gene results in a truncated protein transcript that models variant
late-infantile CLN5 disease. These mice display, similar to patients, a
relatively mild phenotype without severe brain atrophy or prominent
motor abnormalities. By 5 months of age, a progressive visual decline
is evident leading to complete loss of vision [195].
In Cln5−/− mice microglia activation, astrocytosis and defective
myelination are visible from 3 months of age onwards accompanied
by an altered expression level of genes involved in immune response,
myelin integrity and neuronal degeneration [195–197]. Interestingly,
late neuronal loss is reported to become apparent in the cortex before
its onset in thalamocortical regions, which is opposite to the order in
other NCL mouse models [175,183,197,198]. In line with the clinical
features, neurodegeneration is most pronounced in the visual system
[197]. In particular, GABAergic interneurons were found to undergo
cell death [195]. Immunohistochemistry studies on 12 month old
Cln5−/− mice revealed alterations in the distribution and level of
pre-synaptic proteins in the thalamocortical system and the cortex
[197]. Moreover, a dysregulation in cellular metabolism and lipid trans-
port was described in these mice [196].
The Cln6nclf mouse is a naturally occurring mutant mouse that
bears a frame shift in exon 4 of the Cln6 gene causing a short-livedtruncated CLN6 protein [199,200]. These mice develop progressive
retinal atrophy by 4 months of age and rear limb paresis by the age
of 8 months. Autoﬂuorescent inclusions are visible in the murine
brain and spinal cord early on and spread rapidly leading to wide-
spread accumulation of storage material by 6 months of age. Reactive
gliosis, myelin sheath degeneration and localised astrocytosis also be-
come evident [199,201]. Death occurs by 12 months of age [199].
Consistent with other NCL mouse models, evidence for synaptic pa-
thologywas provided in the CLN6mousemodel. The expression level of
synaptic proteins was reported to change ﬁrst in the thalamus and later
in the cortex,whichmay indicate a regional selectivity [187]. A decrease
in GABA and an increase in glutamate and glutamine were detected in
the cortex; in the cerebellum these changes were less pronounced
[201]. ER stress and UPR activation could not be associated with neuro-
nal loss. It was suggested, rather, that an up-regulation or disruption of
the autophagy-lysosomedegradation pathwaymight be involved in the
neurodegeneration of CLN6nclfmice, similar to ﬁndings in Ctsd deﬁcient
and Cln3Δex7/8 mice [177,201,202].
Another naturally occurring mouse model is the Cln8mnd mouse
harbouring a premature stop codon in the Cln8 gene that is the counter-
part of human variant late infantile CLN8 disease [203]. Themice repre-
sent a very similar, yet more aggressive, neurological phenotype to
CLN6nclf mice [199]. In Cln8mndmice on a C57BL/6 background, progres-
sive retinal atrophy and spastic limb paresis commence at an age as
early as 5 weeks and 6 months, respectively. Premature death occurs
by 12 months of age [203,204]. It should be noted that mutant mice
on an AKR background show earlier and more progressive clinical
signs [205].
Before motor deﬁcits become apparent, Cln8mnd mice display
early-onset microglia activation, astrocytosis, up-regulation of pro-
inﬂammatory cytokines and ER stress in the brain or spinal cord
[206–210]. Loss of retinal cells, mostly photoreceptor cells, is found
from P20 onwards and can be linked to oxidative stress [211–213].
Concurrent with the beginning of gait abnormalities, neuronal loss
is detected in the spinal cord and hippocampus; slightly later neuro-
degeneration occurs in the cortex [206,214]. In agreement with the
pathology of other NCL mice, the murine Cln8mnd model shows a
loss of GABAergic interneurons in the CNS [214]. Synaptic pathology
is described in the spinal cord and CNS including an altered expres-
sion of glutamate receptors, increased glutamate levels and neuronal
hyperexcitability [209,215–217]. Regional selectivity, a frequently
reported characteristic in NCL mouse models, is demonstrated for mi-
croglia activation and neurodegeneration with onset in the somatosen-
sory thalamocortical pathway at early disease stages [207,208].
Moreover, Cln8mnd mice reveal behavioural abnormalities, namely
enhanced activity, aggression, poor memory and associative learning
abilities [218,219].
There are four genetically different mouse models for juvenile
CLN3 disease, the most common NCL type in humans. Two knockout
mice were generated by the insertion of a neomycin cassette into the
Cln3 gene to replace exons 7–8 (Cln3ex7/8neo) [220] or exons 1–6
(Cln3Δex1–6) [221]. A knock-in mouse was developed using the cre-lox
technology to excise exons 7 and 8 of Cln3 (Cln3Δex7/8) in order tomimic
the 1 kb deletion in Cln3, the most common disease-causing mutation
[222]. Lastly, a knock-in reporter mouse was designed by replacing
most of exon 1 and all of exons 2–8 with the exogenous reporter gene
LacZ (Cln3lacZ/lacZ); while, the endogenous promoter sequence was not
altered [223]. Thus, this last mouse model allows the study of Cln3 ex-
pression and circumvents the challenges of using antibodies which
has proven difﬁcult due to low endogenous Cln3 expression [223].
Despite, the genetically engineered disruption of the gene se-
quence, it is debated whether partial Cln3 activity may be retained
in the knockout mouse model [224]. Variant mRNA transcripts of Cln3
were detected in Cln3Δex7/8 mice, as in patient samples [222,224], and
the phenotype of cells from patients worsened when CLN3 activity
was further depleted using RNA inhibition. In further support of
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and mild progression of human symptoms such as visual decline,
motor dysfunctions, memory deﬁcits, resting tremor and decreased
overall activity [219–223,225,226]. It is of note, however, that retinal
degeneration was pronounced in Cln3Δex7/8 mice bred on a mixed
129/Sv/CD1 background and that the CD1mouse strain is linked to albi-
nism [222].
At early disease stages the Cln3Δex1–6mousemodel exhibits a slowly
progressive loss of neurons in the striatum, cerebellum and thalamic
nuclei, and sparse atrophy was found in the cortex [198,221,227–229].
Cln3Δex7/8mice show selective loss of thalamic neurons, somatosensory
relay neurons and target neurons within the somatosensory cortex
[229]. Widespread cell death of GABAergic interneurons was reported
at the age of 14 months in Cln3Δex1–6 mice [230]. Interestingly, retinal
cells appeared to be relatively preserved. Degeneration of visual relay
neurons in the LGNd (dorsal lateral geniculate nuclei), reduced con-
duction velocity in the optic nerve and onset of optic nerve degenera-
tion were followed by minimal retinal cell loss in Cln3Δex1–6 mice
[198,231]. The Cln3Δex7/8 mouse model displays a moderate visual phe-
notype including inner retinal cell loss, reduced inner retinal cell func-
tion and altered pupillary light reﬂexes [116,225].
The mechanism underlying neuronal degeneration in juvenile CLN3
disease is not known. Prior to neuronal death in the striatum, a reduced
level and catabolism of dopamine, potentially causing the accumulation
of reactive oxidative dopamine forms, was evident in Cln3Δex1–6 mice.
An altered dopamine catabolism may cause the accumulation of reac-
tive oxidative dopamine forms [227]. An increase in oxidative proteins
was also detected in the cerebellum, thalamus and primary cortex of
these mice further supporting the involvement of oxidative stress in
the neurodegeneration of juvenile NCL [232]. Studies with neuronal
cell cultures derived from Cln3Δex7/8 and Cln3Δex1–6 mice provided evi-
dence that dysregulated autophagy, membrane or vesicle trafﬁcking
and mitochondrial function may play a role in neuronal loss
[202,233,234].
In comparison to other NCL mouse models, Cln3 mutant mice
show an atypical neuroimmune response. Subtle activation of neuroglia
was detected early on in Cln3Δex1–6 and Cln3Δex7/8 mice; however,
astrocytotic proliferation and macrophage formation was not observed
[229,230]. Increased levels of α-fetoprotein (that may act as an
autoantigen) and circulating autoantibodies to glutamic acid decarbox-
ylase (GAD65) were found, supporting the notion of an autoimmune
component to the pathogenesis in juvenile CLN3 disease [235,236].
The presence of GAD65 was associated with elevated levels of presyn-
aptic glutamate, consistent with reported changes in the glutamate/
glutamine cycling of Cln3 deﬁcientmice [236,237]. Other synaptic alter-
ations include reduced levels of GABA and an age-dependent sensitivity
to AMPA and NMDA receptor mediated excitotoxicity [237,238].
4.2. Candidate NCL mouse models
Despite advanced gene sequencing technologies, there are variant
and adult-onset human NCL cases without known disease-causing ge-
netic defects. Mouse models have been discovered that exhibit pheno-
types resembling distinctive NCL features and may represent accurate
models for humanNCL forms. Candidate NCLmousemodels include an-
imals harbouring null mutations in the genes for Cathepsin F (Ctsf), Ppt2
(Palmitoyl protein thioesterase 2) and for two chloride channels (Clcn-7,
Clcn-6). To date, none of the models has been linked directly to human
NCL.
Ctsf is a ubiquitously expressed lysosomal cysteine protease in-
volved in lipoprotein degradation and antigen processing [239–241].
Mice lacking Ctsf show slow progressive widespread accumulation of
autoﬂuorescent storage material in the CNS, motor abnormalities and
seizures [242] — common NCL characteristics. Intracellular inclusions
and motor coordination deﬁcits become apparent at 6 weeks and
12 months of age, respectively, which may point towards a murinemodel for late onset NCL. However, the adult-onset NCL diseases tested
so far did not bear mutations in the Ctsf gene [242].
The gene Ppt2 is another candidate for late onset NCL and encodes a
lysosomal thioesterase homologous to the protein Ppt1. Ppt2 null
mutant mice (Ppt2−/−) display an NCL-like phenotype including
autoﬂuorescent storage material in brain, neuronal cell death and
motor defects with an onset later than Ppt1 deﬁcient mice [180,243].
Unlike themajority of NCLmousemodels, however, visceral features af-
fecting pancreas, bone marrow and spleen were observed in Ppt2−/−
animals [243].
Mice carrying mutations in the Clcn-7 and Clcn-6 genes of the
voltage-gated chloride channel family CLC have been proposed as puta-
tive NCLmousemodels [244,245]. CLCs reside in the plasmamembrane
and intracellular organelles to exert functions like the regulation of
chloride levels and the acidiﬁcation of vesicles. The disruption of Clcn
genes leads to a variety of disorders with osteopetrotic, hepatic and
neurodegenerative manifestations [246,247]. Mice lacking Clcn-7 and
Clcn-6 reveal pathological features of NCL disease, however, features
are also present that are not found in human NCL patients.
A Clcn-7 mutant mouse (Clcn-7−/−) designed to abolish protein
expression completely was reported to develop severe osteopetrosis,
widespread neuronal and retinal degeneration, autoﬂuorescent
intralysosomal inclusions and premature death at 7 weeks of age
[244,248]. Clcn-7 deﬁcient mice exhibit localised astrocytosis and
microglial activation within the somatosensory thalamocortical sys-
tem, loss of thalamic relay neurons and cortical interneurons, features
that are evident in multiple forms of NCL [175,183,197,249]. A sponta-
neous mutation in Osmt1, a functionally important β-subunit of Clcn7,
leads to a phenotype closely resembling Clcn-7−/−mice [249,250]. Re-
cently, another Clcn-7 mutant mouse model was generated bearing an
alternate Clcn-7 transcript. Thesemicepresentwith early onset and rap-
idly progressive neurodegeneration similar to the complete loss of
Clcn-7; interestingly, osteopetrosis is absent. The lack of osteopetrosis
results from the expression of alternative splicing transcripts in bones
indicating that neuronal and retinal degeneration may not originate
from osteopetrotic compression of the brain [251]. Based on these ﬁnd-
ings Clcn-7mutant mice may act as a model for human congenital NCL
disease [249,251]. In contrast, the disruption of Clcn-6, a channel exclu-
sively expressed in neurons, is debated to give rise to amousemodel for
milder forms of human NCL. Clcn-6−/− mice have a normal life span
with slowly progressing neurodegeneration, distinct accumulation of
storage material and mild behavioural abnormalities [245]. The mice,
however, do not show evidence of localised thalamic glial response,
loss of thalamic relay neurons or interneuron population in the cortex
and hippocampus which are well-deﬁned neuropathologic characteris-
tics of NCL mouse models [171,249]. Initially, two NCL patients were
found to carry a single mutation in the CLCN-6 gene on one chromo-
some [245]; yet, one of the patients was lately identiﬁed to be homozy-
gous for mutation in the Cln5 gene [252]. CLCN-7 mutations have not
been reported yet in NCL disease patients. Nevertheless, it cannot be ex-
cluded thatmutations in CLCN-6 or CLCN-7may account for new or rare
forms of human NCL disease.
4.3. Development of experimental therapies
NCL mouse models have been used to evaluate the feasibility and
efﬁciency of different therapeutic interventions. An important consider-
ation for the design of a therapy is the solubility of themutated protein.
There are generally two classes of proteins affected in NCL, mutations
occur either in a soluble lysosomal enzyme or in a transmembrane pro-
tein. The replacement of a soluble enzyme is aided by the phenomenon
of cross-correction. Functional enzyme restoration in a small cohort of
cells with functional enzyme can be therapeutic as the enzyme can be
secreted from expressing cells and taken up by neighbouring cells via
the mannose-6-phosphate pathway. The phenomenon does not apply
to transmembrane proteins and the currently available techniques
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ducing the likelihood of a therapeutic effect [253].
A powerful strategy to restore the function of a mutated soluble en-
zyme is enzyme replacement therapy (ERT) [253,254]. In mice
mirroring CLN1 disease intravenous administration of high levels of
the Ppt1 enzyme leads to an improved neuropathology in the thalamus,
a later onset ofmotor deterioration and increased survival. Beneﬁcial ef-
fects are pronounced in animals treated from birth [255]. Interestingly,
major organs take up rapidly intravenously injected Ppt1 enzyme and
clearance of autoﬂuorescent material occurs outside the CNS [256].
Thus, this approach may be utilised to treat systemic pathology in NCL
mouse models with defective soluble proteins. In Tpp1−/−mice, intra-
ventricular and intrathecal deliveries of the Tpp1 enzyme cause an at-
tenuated neuropathology, improved neurological phenotype and
longer lifespan [194,257].
In order to achieve a long-term therapeutic expression level of a
protein, gene therapy using adeno-associated virus (AAV) appears to
be a promising strategy [253]. The viral delivery of Ctsd to the brain
of mice lacking Ctsd activity prolongs lifespan and diminishes neuro-
logical and visceral symptoms [258,259], though ceroid accumulation
and microglia activation are not prevented [259]. In Tpp1−/− mice
AAV-mediated gene therapy leads to increased longevity and better
performances in motor or behavioural tasks. Neuropathologically, a
reduction in reactive gliosis, autoﬂuorescent inclusions and axonal
degeneration is detectable [260–262]. In accordance with ERT on
Ppt1−/− mice, early AAV treatment appears to be more effective
[260]. The ﬁrst clinical trial on patients suffering from classic late in-
fantile CLN2 disease was carried out and long-term follow-up studies
are ongoing [263]. CNS-directed gene therapy in Ppt1 deﬁcientmice re-
sults in reduced autoﬂuorescent material, and improvement in brain
histology and behavioural assessment, yet no increase in longevity
[264,265]. Surprisingly, intracranial injection of recombinant Ppt1 com-
bined with bone marrow transplants dramatically enhances motor
performance and lifespan, an effect not achieved by bonemarrow trans-
plantation alone [266].
Hope for NCL disease therapies has also arisen from work with
human stem cells. To prevent xenograft immune rejection, Ppt1−/−
knockout mice were back-crossed on the NOD (non-obese diabetic)-
SCID (severe combined immunodeﬁciency) background and non-
genetically modiﬁed human CNS stem cells (huCNS-SCs) were trans-
planted into the brain at neonatal time points. Following treatment
the animals show a reduction in autoﬂuorescent material, neuro-
protection of host CA1 neurons and delayed motor coordination loss
[267]. A similar study is ongoing for Tpp1−/−/NOD-SCIDmice. Evidence
is emerging that grafted huCNS-SCs are able to adopt neuronal fate in
immunodeﬁcient Tpp1−/− animals. It is under investigation whether
the engrafted cells are also capable of delivering TPP1 enzyme to the
murine brain [268]. Transplantation of huCNS-SCs has been carried
out in infantile and late-infantile NCL patients in the course of a phase
I clinical trial. One patient has died without detectable toxic effects
towards the transplant; the remaining patients are undergoing post-
surgical examination.
The development of therapies is problematic for transmembrane
forms of NCL disease as cross-correction does not occur for the major-
ity of transmembrane proteins. ERT, gene therapy and stem cell trans-
plantation have not been described for mutated transmembrane
proteins in NCL. However, pharmacological approaches demonstrate
therapeutic effects in murine models. In Cln3Δex1–6 mice low adminis-
tration of EGIS-8332, an agent that attenuates AMPA receptor activity,
or memantine, a NMDA receptor antagonist, leads to better perfor-
mances in motor tasks [269,270]. Similarly, other pharmacological
compounds delay the onset of motor abnormalities in CLN8mnd mice;
however, beneﬁcial long-term effects are minimal [271–274]. Interest-
ingly, treatment with the immunosuppressant agent mycophenolate
moteﬁl signiﬁcantly reverses motor dysfunction and neuroinﬂamma-
tion in Cln3Δex1–6 mice [275].4.4. Summary
Mouse models have enormously contributed to a better under-
standing of the pathology and progression of the various forms of
NCL. Each mouse model displays distinct features mirroring the
human disease with behavioural and motor deﬁcits, neuronal cell
death and accumulation of storage material. Thorough histologic
analyses point to a regional selectivity of pathogenic events in all
models. The thalamocortical system seems to be important for the
onset of pathological changes since astrocytosis and microglia activa-
tion occur ﬁrst in this region followed by prominent neuronal cell
loss. The mechanism underlying neurodegeneration is not under-
stood yet and a range of processes is reported including apoptosis,
autophagy and oxidative stress. Another feature present in several
models is the molecular changes at the presynapse which may also
play a role in neurodegeneration. The detailed description of the dis-
ease pathology also provides good parameters for the evaluation of
candidate NCL mouse models. To date, no mouse models are available
for adult or rare variant forms of human NCL; however several are
under investigation.
Considerable progress has been made towards the development of
therapeutic treatments for NCL. Now, it is possible to deliver functional
protein to the murine brain through ERT, AAV-mediated gene therapy
and stem cell transplantation for themajor forms of CLN1 and CLN2dis-
ease. Most of these treatments appear safe and cause a delay in the
onset and progression of the disease pathology. Interestingly, the com-
bination of gene therapy and BMT leads to sustainedmotor function im-
provement and extended lifespan in Ppt1−/−mice [266].
Only a few therapeutic studies are available for NCL forms with
defective transmembrane proteins. The most promising results are
obtained following mycophenolate moteﬁl administration to Cln3Δex1–6
mice including a reduction in motor deﬁcits and neuroinﬂammation
[275].
It is evident that the current approaches are not sufﬁcient to deliv-
er effectual amounts of functional protein to the CNS in order to pre-
vent disease pathology and premature death of the animals. The main
obstacles for therapies targeting the CNS are the large size of the brain
and the presence of the blood brain barrier (BBB). Only very small
lipid-soluble molecules can passively enter the brain or spinal cord
and the vast majority of produced therapeutic substances cannot
cross the BBB effectively [276].
One strategy to overcome these difﬁculties is to enhance AAV-
mediated delivery of proteins to the brain. In a mouse model of
mucopolysaccharidosis type VII, an inherited lysosomal storage disor-
der, ventricular injection of recombinant AAV2/4, a virus serotype
demonstrated to transduce ependymal cells, resulted in a widespread
enzyme secretion and attenuation of CNS deﬁcits [277]. A similar ap-
proach reveals promising results in Tpp1 deﬁcient dogs [89]. More-
over, single intrathecal injections of self complementary (sc) AAV9
vectors indicate an increased efﬁciency of gene delivery compared
to traditional single stranded (ss) AAV vectors. The disadvantage of sc
AAV vectors, however, is their limited size for packaging DNA [278].
Intravenously administrated sc AAV9 vectors have recently been
shown to be able to cross the BBB with prolonged expression in the
CNS, thereby presenting a potential delivery route to the brain for
NCL therapies [279,280]. Interestingly, an extensive transduction of
the entire CNS was also achieved by intravenous administration of
AAV9 in neonatal and foetal mice [281,282]. These ﬁndings give par-
ticular hope for treatments of early onset and aggressive forms of NCL.
Another interesting insight emerges from a study in Cln3Δex1–6mice
showing that autoantibodies are capable of overcoming the BBB via a
size-selective breach [283]. It is not understood how the integrity of
the BBB is compromised; however, it may present a potential delivery
route for drug supply to the CNS in NCL. The administration of the
immunosuppressant mycophenolate moteﬁl causes a reduction in
neuroinﬂammation and motor deﬁcits in Cln3Δex1–6 animals [275].
Fig. 2. Immunoﬂuorescence staining of microvilli in the eye of zebraﬁsh following cathepsin D (CD) knock-down and rescue. Immunoﬂuorescence staining of α-actin (red) in eye
sections derived from 4 dpf micro-injected larvae (CTRL=control injections; S-MPO=splicing morpholino; T-MPO=translation morpholino; RESCUED=translation morpholino
plus 200 pg/egg of mutant CD mRNA). Nuclei are stained with DAPI (blue). The arrow points to the microvilli of retinal pigmented epithelium (RPE) cells. Note the absence of this
structure in T-MPO zebraﬁsh. The photoreceptor cell (PRC) layer is indicated by curly brackets. Scale bar is 10 μm. Images representative of ﬁve (three for RESCUED) independent
experiments.
Reproduced with permission [294].
1852 M. Bond et al. / Biochimica et Biophysica Acta 1832 (2013) 1842–1865Currently, a clinical trial is underway to evaluate the safety and toler-
ance of the agent in juvenile CLN3 disease patients [284].
5. Zebraﬁsh
The zebraﬁsh is a small freshwater tropical ﬁsh. The major advan-
tages of this vertebrate is that adults produce large numbers of small
offspring, which are externally fertilised, meaning that they can be
manipulated and monitored as whole animals from fertilisation on-
wards. Offspring can be raised to be transparent, enabling an excel-
lent view of internal organs and speciﬁc markers, in the live animal.
Being diploid, zebraﬁsh have been traditionally used for mutational
analysis, enabling researchers to establish the functions of the pro-
teins encoded by each gene that is mutated. In such a way, both for-
ward and reverse mutagenesis screens in zebraﬁsh have proved
invaluable for understanding how development is genetically con-
trolled in a vertebrate. However, there are still many hundreds of mu-
tants for which we still do not know the underlying mutation — a
potentially rich source of NCLmodels. Mutation analyses are supported
by the sequencing and assembling of the zebraﬁsh genome, although
errors persist in the databases (ENSEMBL and NCBI) and require correc-
tion bymanual annotation. Zebraﬁsh are also amenable to other genetic
and chemical manipulations such as knockdown of genes using anti-
sense morpholino oligonucleotides, overexpression of genes using
mRNA injection or transgenic constructs, generating mosaics, andmodulation of proteins by adding chemicals to their water. Although
most of these techniques are possible in adult zebraﬁsh, the embryonic
and larval stages are most suitable as they are small, it only takes a few
days for animals to reach the right stage for an assay, and they can be
cultured and assayed in very large numbers with minimal care in Petri
dishes or multi-well plates, meaning that many experiments can be
highly-powered. More recently, these techniques have been employed
to improve our understanding of the function of disease proteins, to
generate disease models, to screen chemical libraries for molecules
that modify the phenotype, and to test chemicals for therapeutic efﬁca-
cy, toxicity and teratogenicity [171]. With the development of automa-
tion for the collecting, sorting and arraying of zebraﬁsh embryos and
larvae, and of more high-throughput assays, the zebraﬁsh promises to
provide an excellent model for drug discovery.
5.1. Zebraﬁsh have homologues of many NCL genes
The ﬁrst zebraﬁshNCL gene to be publishedwas cln2 (now renamed
tpp1), and since then, only cln7, cln10 and cln11 have been published.
There is one orthologue of each of these genes. Cross-referencing the
ENSEMBL database with ZFIN (the zebraﬁsh database) reveals at least
one homologue of all known NCL genes (see columns 1–4 in Table 4).
There are single gene orthologues of CLN1, CLN2, CLN3, CLN5, CLN8,
CLN10, CLN12, CLN13, CLCN6 and SGSH. However, parts of the zebraﬁsh
genome underwent duplication during teleost evolution (reviewed
Table 4
Summary of zebraﬁsh CLN genes and models with conﬁrmed or suggested NCL.
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CLN1, Ppt1 ppt1 ENSDARG00000039980 ZFIN ppt1sa9 Nonsense Predicted protein truncation after exon2 nd ZMP
ppt1sa7888 Nonsense Predicted protein truncation after exon 3 nd ZMP
CLN2, TPP1  tpp1 ENSDARG00000042793 ZFIN; 
[296]
tpp1sa11 Nonsense Predicted protein truncation after exon 3 
(out of 13)
Small eyes and head at 
5dpf
ZMP; 
[293]
tpp1sa2895 Essential splice site exon 9  (out of 13) nd ZMP
tpp1sa6483 Nonsense Predicted protein truncation after exon 10  
(out of 13)
nd ZMP
tpp1hu3587 Nonsense Predicted protein truncation after exon 11 
(out of 13)
Normal ZMP
CLN3 cln3 ENSDARG00000037865 ZFIN cln3sa8139 Nonsense Predicted protein truncation after exon 12 
(out of 15)
nd ZMP
CLN4; DNAJC5 dnajc5aa ENSDARG00000042948 ZFIN
dnajc5ab ENSDARG00000004836 ZFIN
dnajc5ga ENSDARG00000041896 ZFIN
dnajc5gb ENSDARG00000017687
dnajc5b ENSDARG00000058147
CLN5 cln5 ENSDARG00000076339; 
ENSDARG00000060907 
(needs correct annotation)
None
CLN6 cln6a ENSDARG00000077584 ZFIN; 
[123]
cln6sa904 Essential splice site Exon 6 (out of 7) nd ZMP
cln6b ENSDARG00000090002
CLN7, MFSD8 mfsd8 ENSDARG00000015179 ZFIN; 
[287]
mfsd8sa2646 Essential splice site Exon 5 (out of 12) nd ZMP
mfsd8la018118Tg retroviral insertion nd nd [297]
ENSDARG00000087525 None
ENSDARG00000076959 None
CLN8 cln8 ENSDARG00000075525 None
CLN10, 
Cathepsin D
ctsd ENSDARG00000057698 [298] CD T-MPO antisense 
morpholino 
oligonucleotide
na Complete protein knockdown Micropthalmia (RPE 
microvilli  affected), 
shorter body, swim 
bladder not inflated, 
hyper-pigmentation, 
impaired yolk absorption 
(all at 4dpf), premature 
death (10dpf)
[294]
CLN11, 
Progranulin
grna ENSDARG00000004954 [288] grnasa6034 Nonsense Predicted protein truncation after exon 17, 
18 or 22 (out of 19, 24 and 20 exons is each 
respective transcript)
nd ZMP
grnasa5206 Nonsense Predicted protein truncation after exon 5, 6, 
or 6 (out of 19, 24 and 20 exons in each 
respective transcript)
nd ZMP
zfPGRN-A ATG MO and 
zfPGRN-A 5'UTR MO 
antisense morpholino 
oligonucleotide
na severe protein knockdown Reduced motility, 
widespread disruption of 
CNS development, 
motoneuron axon 
truncation and premature 
branching
[289]
pgrnA ATG MO and 
pgrnA 5'UTR MO  
antisense morpholino 
oligonucleotide
na nd motoneuron axon 
truncation
[290]
grnb ENSDARG00000025081 [288] granulinB GT- grip 
antisense grip 
oligonucleotide
na 50% knockdown No phenotype [291]
pgrnB ATG MO and 
pgrnB 5'UTR MO  
antisense morpholino 
oligonucleotide
na
nd=not reported; na=not applicable.
1853M. Bond et al. / Biochimica et Biophysica Acta 1832 (2013) 1842–1865within [286]) and so there are more than one potential orthologue for
the other CLN genes — only further analysis of expression and function
will allow us to determine which genes are the true orthologues, orif each orthologue has functional subspecialisation. For those with sev-
eral possible orthologues, the proposed true orthologue is shown in
bold in Table 4 (if known). For CLN7, Aiello et al. [287] and ZFIN both
1854 M. Bond et al. / Biochimica et Biophysica Acta 1832 (2013) 1842–1865consider ENSDARG00000015179 to be the true orthologue, due to the
level of sequence conservation. In the case of CLN11, grna/
ENSDARG00000004954 is considered to be the most likely orthologue,
based on conservation levels, gene structure, expression and phenotyp-
ic analyses [288–290], yet phenotypic analysis suggests that grnb/
ENSDARG00000025081 might also retain some function of relevance
to NCL [290], although an independent knockdown experiment pro-
duced no phenotype [291]. For CLN14, ZFIN considers kcnd7/
ENSDARG00000061580 to be the true orthologue due to the level of
conservation. A lack of information leaves us unable to determine if
any of the CLN4 and CLN6 genes are more orthologous than the others.
5.2. Zebraﬁsh models of NCL
The expression of several cln genes can be found in publications and
on ZFIN (column 4 in Table 4), and the consequences of gene knock-
down are also summarised (column 5–9 in Table 4). At the time of
writing, very few of the available disease models have been studied
(denoted as nd in column 8 of Table 4). Clearly, we still know very little
about most of the zebraﬁsh cln genes and the consequence of their ma-
nipulation, illustrating the lack of exploitation so far of this versatile
model organism for NCL research. In the rest of this section, we focus
on the studies describing knockdown phenotypes for cln2 (tpp1),
cln10 (ctsd) and cln11 (grna and grnb).
An image of the zebraﬁsh tpp1sa11 mutant is reported on the
Zebraﬁsh Mutation Project (ZMP) database (http://www.sanger.ac.uk/
cgi-bin/Projects/D_rerio/zmp/gene.pl?id=ENSDARG00000042793) and
the homozygousmutant has smaller eyes and head compared to its nor-
mal siblings at 5 days post-fertilisation (dpf). This phenotype is caused
by a premature termination codon (PTC; nonsense mutation) in exon
2. A secondmutant, tpp1hu3587, however, has no phenotype, presumably
because the nonsense mutation is in exon 11 and enough protein of a
sufﬁcient length is produced. Abstracts presented at previous confer-
ences [292,293] have demonstrated that the tpp1sa11 mutant does in-
deed show the hallmarks of NCL [292,293]. Not only does this provide
a validated zebraﬁsh model of CLN2 disease, but we now also know
what phenotypes to expect when screening for NCL mutants.
Knockdownof the zebraﬁsh ctsd genewas performedby the injection
of a ctsd-speciﬁc antisense morpholino oligonucleotide (CD T-MPO),
causing a small eye phenotype, loss of swim bladder, shorter body,
hyper-pigmentation, poor yolk absorption and premature death [294].
The authors demonstrated that the small eye was accompanied by the
absence of retinal pigmented epithelium (RPE) microvilli at 4 dpf,
suggesting that the RPE may not be properly formed or may degenerate
in CLN10 disease (Fig. 2). Although the phenotype is consistent with the
zebraﬁsh tpp1mutant, it is not yet clear whether CD T-MPO-injected ﬁsh
display the hallmarks of NCL — further investigation will be needed.
Mutations in progranulin were recently shown to cause CLN11
disease, although it was previously demonstrated that autosomal domi-
nantmutations cause frontotemporal lobar degeneration (FTLD). Hence,
the few studies on zebraﬁsh Progranulin have focused on its role in FTLD
and its associationwith TARDNAbinding protein-43 [289–291]. Howev-
er, to explore the function of the zebraﬁsh progranulin genes, grna and
grnbwere knocked downby antisense oligonucleotide injection, ameth-
od which essentially replicates the molecular defect in CLN11 disease. It
appears that both grna and grnb can cause truncation of motoneuron
axons [289,290] and grna knockdown causes disruption of the CNS
early in embryonic development (thiswas not studied in the grnb knock-
down). It remains to be seen if motoneuron axon defects exist in CLN11
patients and how well these ﬁsh model NCL.
One common theme from these studies is that in zebraﬁsh the tpp1,
ctsd10 and pgrna/grnb genes would be considered to be developmental
genes, as phenotypes begin during embryonic stages, suggesting that
prenatal changes may occur in humans with these forms of NCL. Alter-
natively, this may simply reﬂect the lack of maternal support available
to the developing zebraﬁsh.5.3. Development of experimental therapies
Recently, the tpp1sa11 mutant was used to determine if premature
termination codon readthrough drugs might be a valid therapeutic
approach to follow, given that there are two new drugs available
that are in clinical trial for cystic ﬁbrosis and Duchene muscular dys-
trophy. Russell and Mahmood reported that tpp1sa11 mutants had in-
creased mortality compared to their normal siblings when treated
with one of these drugs (Ataluren), with no signiﬁcant phenotypic im-
provement [295]. This implies that patients with CLN2 disease may
not ﬁnd this class of drug beneﬁcial and may even ﬁnd it more toxic
than healthy people will. This warrants further examination using
mammalian models and patient tissues, and should be kept in mind
when prioritising experimental therapies.
5.4. Summary
Although the use of zebraﬁsh for NCL research is still in its infancy,
these studies demonstrate the potential of this model organism for
disease modelling, mechanistic studies, and experimental therapy
testing. However, the speciﬁc future contribution of zebraﬁsh studies
will largely depend on how well each zebraﬁsh model of NCL repli-
cates the disease and what phenotypes they display at what stage of
life. For example, the validated model of CLN2 disease is well-suited
to all of those studies as the phenotype presents during embryonic
stages and rapidly progresses, while displaying locomotion pheno-
types that can be assayed in a high-throughput manner. It is likely
that this model, and hopefully other models in the future, will be
used in drug discovery for CLN2 disease.
6. Fruitﬂy, Drosophila melanogaster
The fruitﬂyD.melanogasterhas a long history of use as a ‘gene discov-
ery’ organismdue to its genetic amenability and short generation time. It
has been used extensively in classical genetic studies to identify genes
active in a variety of biological processes including development, ageing,
cell signalling, cell adhesion, behaviour and learning [299,300]. A large
number of the genes identiﬁed in these screens have been revealed to
have homologueswith the same functions in higher organisms including
humans, contributing greatly to the identiﬁcation of the genetic path-
ways underlying a variety of biology. Recently, Drosophila has been in-
creasingly used to both model human disease and elucidate the normal
functions of the genes affected in human disease [301]. About 70% of
the genes affected in human disease are conserved within Drosophila
and these genes can be manipulated to generate pathologies similar to
that seen in humans [302]. Furthermore, the large number of genetic
and cell biological tools available for Drosophila allows themanipulation
and study of gene function at a ﬁne level in vivo [303]. Many investiga-
tions have involved the expression of human disease genes within
Drosophila to characterise their activity, identify genetic partners in
vivo or allow medium throughput screens of modiﬁer compounds
[304–306]. In particular, Drosophila has been utilised to model a
variety of neurodegenerative disorders including Alzheimer's disease,
Parkinson's disease, several spinocerebellar ataxias and fragile X syn-
drome among others [307]. Drosophila is now beginning to be used to
aid the study of neuronal ceroid lipofuscinosis where it has contributed
to the growing understanding of the molecular basis of the disease and
may also provide an additional platform for thedevelopment of therapies.
6.1. Drosophila contains homologues of a subset of the NCL proteins
Drosophila contains homologues of the genes affected in CLN10 dis-
ease (cathepsin D; cathD), CLN1 disease (Ppt1), CLN3 disease (Cln3) and
CLN7 disease (Cln7). It is likely that the Drosophila proteins have similar
functions to their human counterparts as the Drosophila proteins show
1855M. Bond et al. / Biochimica et Biophysica Acta 1832 (2013) 1842–1865strong conservation; Drosophila cathepsin D (CathD) has a 65%
amino acid similarity [308], Ppt1 has 75% similarity [309], Cln3
shows 60% similarity [310] and Cln7 has 56% amino acid similarity
to the human form [311]. The ﬂy Ppt1 also has the same thioesterase
activity as the human protein [309]. As with the human proteins it
has proven difﬁcult to obtain antibodies to detect the expression
patterns of the Drosophila NCL proteins in vivo. However, the ex-
pression of tagged forms of the proteins reveals that Ppt1, Cln3
and Cln7 are found to be localised to the lysosome, although at
high levels of expression some proteins can be detected in addition-
al locations including the plasmamembrane [310,312] (Tear Labora-
tory, unpublished observations). RT-PCR has revealed that Ppt1 and
cathD are expressed at low levels fairly ubiquitously [308,309], thus
the ﬂy forms display similar properties and expression patterns as
the human proteins.6.2. Drosophila provides models of human NCL disease
Although Drosophila does not have homologues of all the genes af-
fected in the different NCLs, it is likely that the NCL genes in Drosophila
are performing core functions that are necessary for normal neuronal
health and their function is likely to be similar to the function of the
human genes. Drosophila resources are now available for the study of
cathD, Ppt1 and cln3 (Table 5),where the effects of loss or gain of activity
of the genes can be studied, while models for cln7 are being developed.
Loss of function mutations in these genes give rise to phenotypes that
bear many of the hallmarks of the human disorders. Mutations in
cathD and Ppt1 both lead to the accumulation of autoﬂuorescent mate-
rial within the brain and the deposition of electron dense material. In
the CLN10 disease model the storage material is granular with some la-
mellar elements resembling those seen in ovine congenital NCL [308]. In
the CLN2 disease model the deposits are spherical and composed of a
granular core surrounded by concentric layers of electron densemateri-
al [313]. Similar phenotypes are also observed in mutations in the pre-
dicted lysosomal sugar carrier spinster (also known as benchwarmer)
[314–316] although the human homologue of this gene has not yet
been associated with an NCL disorder. Thus loss of NCL genes in Dro-
sophila results in pathologies related to the human disease. In common
with human patients the absence of either the Ppt1 [313] or cln3 [317]
gene leads to a shortened life span, while loss of cathD [308] results in
a moderate amount of neurodegeneration and loss of Ppt1 shows
some modest disruption to the CNS [318]. Studies in Drosophila have
also indicated that the level of expression of the NCL genes is important
since targeted overexpression of Ppt1 or cln3 in the eye using the
UAS-GAL4 system causes neural degeneration resulting in a deformed
eye [310,319]. This pathology is dependent on increased NCL gene ac-
tivity since overexpression of a truncated form of Cln3, similar to that
of the common JNCL allele, or mutated versions of Ppt1 lacking enzy-
matic activity does not show any degeneration. Furthermore, these
phenotypes are speciﬁc to an increase in NCL gene function since
over-expression of other lysosomal proteins, such as Lamp, does not
show the phenotype [310]. The overexpression phenotypes are likely
to be due to the activation of the same pathways as the human proteins
since overexpression of human CLN3 in the Drosophila eye also gives
rise to the same neurodegenerative pathology. The phenotypes induced
by Cln3 overexpression, in the wing as well as in the eye, are indicative
of an impact on Notch and JNK signalling [310]. Further large scale ge-
netic screens have begun to reveal a common role for the Drosophila
NCL genes in signalling and membrane trafﬁcking and indicate that
they are required for normal synapse function (see below). Similar
roles have been previously suggested for spinster, as mutations in spin-
ster lead to defects in endocytosis and synapse function [314–316].
These observations overlap with those emerging from a number of ver-
tebrate studies that suggest that synaptic failure may be a common
early pathology in NCLs [175,185–187].6.3. Genetic screens in Drosophila identify pathways requiring NCL gene
function
Since the identiﬁcation that the Drosophila NCL genes show very
similar properties to the human forms recent work has focused on
the identiﬁcation of genetic partners and pathways that require NCL
gene function. This has been performed by second site genetic modiﬁ-
er screens, which allow the unbiased identiﬁcation of genes that
modify the phenotypes caused by overexpression or loss of function
of the Drosophila NCL genes when they are also knocked out or over-
expressed. Large scale screens have been performed to identify mod-
ulators of Ppt1 and Cln3 activity [317,320,321], whereas a smaller
scale investigation has been performed to identify candidate partners
for cathepsin D [322]. To simplify mass screening the large scale
screens have sought genes that modify the degeneration of the eye
caused by overexpression of Ppt1 or Cln3. These screens have identi-
ﬁed twenty-seven genes that modulate the activity of Ppt1 and
thirty-eight genes that modulate the activity of Cln3. Although the
same genes have not been identiﬁed in the different screens, it is
clear that modulation of several common biological pathways inﬂu-
ences the function of Ppt1 or Cln3. The major activities identiﬁed in
the screens include genes required for endocytosis and membrane
trafﬁcking (e.g. endophilin A, srp9, blue cheese), genes required for
protein stability (e.g. fat facets (a ubiquitin protease), CG5823 (an E2
ubiquitin conjugating enzyme)), genes required for signalling and
transcription (e.g. saxophone (TGF-B receptor type I), kayak (fosB)),
RNA stability or processing (e.g.mago nashi, boule) and genes required
for stress response (e.g. Hsc70-3, mekk, JafRac). Since many of the
genes fall into a relatively small number of classes it appears that the
NCL genes may function within similar cellular processes. The failure
of the screens to identify the same genes could be due to the screening
of different mutant collections or that the different NCL genes affect
similar biology via different pathways.
Not only do these genes modify phenotypes generated by an in-
crease in NCL gene function but, where they have been tested, the
same genetic pathways also appear to be affected in the Drosophila
models mimicking the recessive disorders. Endocytosis is signiﬁcantly
compromised in Drosophila lacking Ppt1 function, where uptake of
ﬂuorescent avidin or HRP is impaired, the tracer is not efﬁciently
transferred to the lysosome and the ultrastructure of specialised
membranes necessary for endocytosis is abnormal [320]. Additionally
a Drosophila model of CLN3 disease, which lacks Cln3 activity, is hy-
persensitive to oxidative stress. These animals have a reduced ability
to survive exposure to reactive oxygen species (ROS) and show a
slight increase in ROS levels under normal conditions. It appears
that the cln3 mutant animals remain able to sense an accumulation
of ROS but are unable to mount the appropriate response [317].
A smaller scale screen looking for genetic partners for cathDmade
use of a model of CLN10 disease. Loss of CathD function in Drosophila
causes a mild degeneration of the retina and this pathology could
be enhanced by reducing the activity of shibire, heat-shock cognate 4,
or thioredoxin reductase-1 or by increasing the activity of target of
rapamycin or Columbus, an HMG-Co-reductase, suggesting that loss
of cathD may also affect endocytosis or reduce the animal's ability to
combat oxidative stress leading to potential failure in lipid metabo-
lism [322]. Overexpression of shibire, the Drosophila dynamin, also
enhances the Ppt1 overexpression phenotype revealing a potential
common pathway requiring Ppt1 and cathepsin D [320].
6.4. Drosophila models indicate a role for CLN genes at the synapse
The Drosophilamodels have identiﬁed a discrete number of cellular
processes where changes may lead to the symptoms associated with
the NCLs and candidate genes that could mediate the disease. Although
many of the processes have been identiﬁed using non-neuronal tissues
these Drosophila studies implicate NCL gene function with roles in
Table 5
Summary of Drosophila NCL models and transgenics for studying NCL.
Human gene Drosophila strain Genetic mutation Molecular defect Phenotype Reference
Cathepsin D,
CLN10
CathD1 Deletion of exon1 70% of protein coding
region deleted
Storage material, autoﬂuorescent
inclusions, mild neurodegeneration
[308]
UAS:CathD None Overexpression construct None reported [208,322]
Ppt1, CLN1 Df(1)446-20 Chromosomal deletion of
Ppt1 and 3 additional genes
No enzyme activity Storage material, autoﬂuorescent
inclusions, shortened lifespan
[309,313]
Ppt1S77F Ser 77 to Phe missense No enzyme activity Storage material, autoﬂuorescent
inclusions, shortened lifespan
[313]
Ppt1A179T Ala 179 to Thr missense No enzyme activity Storage material, autoﬂuorescent
inclusions, shortened lifespan
[313]
UAS:Ppt1-RNAi8/7 RNA interference 10% enzyme activity Some storage material [313]
UAS:Ppt1-8.1 None Overexpression construct Photoreceptor degeneration, apoptosis [319]
UAS:Ppt1-S123A Ser 123 to Ala missense Catalytic inactive
overexpression construct
None [319]
CLN3 Cln3ΔMB1 Deletion of exon 1 & 2 N terminal deletion Reduced life span, hypersensitive to ROS [317]
UAS:Cln3 None Overexpression construct [310]
1856 M. Bond et al. / Biochimica et Biophysica Acta 1832 (2013) 1842–1865endolysosomal trafﬁcking, vesicle cycling, BMP and JNK signalling, RNA
metabolism and oxidative stress. Several of these roles are also emerg-
ing from vertebrate NCL models and defects in these processes are
linked to other neurodegenerative disorders [185,323]. Many of these
roles are required at the synapsewhere they act as important regulators
of synaptic function. Synapse vesicle and membrane trafﬁcking are es-
sential for normal synapse function both for signal transmission and
synapse plasticity. The latter is monitored via BMP signalling between
the pre and post synaptic partners [324] and can be modulated by con-
trolling gene expression from ribonucleoprotein particles sequestered
at the synapse [325,326]. The synapse is also sensitive to oxidative
stress and the impairment of ROS clearance can affect synapse function
[327,328]. Thus studies using Drosophila as a model for NCL have led to
the emerging hypothesis that the NCLsmay be a consequence of synap-
tic deﬁcits leading to neuronal dysfunction. Recent work has begun to
reveal that cln3 and cln7 may both be required to maintain synaptic
morphology, as the larval neuromuscular junction synapse fails to ma-
ture appropriately in the absence of either of these genes (Tear labora-
tory, unpublished observations). This hypothesis and the roles of the
genes identiﬁed asmediators of the disease need to be veriﬁed and test-
ed in vertebrate models yet it is likely that the Drosophila models will
have revealed key genetic pathways affected in the disease and opened
up potential new therapeutic targets. In the future Drosophilawill con-
tinue to give insight into the pathways where the NCL genes function
and also provide a novel platform for the testing and development of
therapies.
7. Yeast
The budding yeast Saccharomyces cerevisiae and the ﬁssion yeast
Schizosaccharomyces pombe are two of the best-characterised eukaryot-
ic model systems. Both are highly amenable to genetic manipulation
and analysis, have short generation times and reproduce in a genetically
stable manner. In addition, yeast recapitulates many fundamental as-
pects of mammalian cell biology. These experimental advantages have
motivated the development of an array of tools for the analysis of
gene function and cell biology in these yeast species, including genome
wide knock-out and GFP-fusion libraries. Consequently, yeast has been
extensively utilised as an experimental system, and is rapidly emerging
as a powerful model for the cell biology of neurodegeneration [329].
7.1. Yeast models for NCL
S. cerevisiae and Sz. pombe have both been proven as valuable tools
in the investigation of NCL biology. S. cerevisiae contains orthologues
of the NCL genes CLN3 and CLN10, whereas CLN1, CLN3 and CLN10are conserved in Sz. pombe (Table 6). The budding and ﬁssion yeast
orthologues of CLN3 (BTN1 and btn1 respectively) have been studied
extensively. Inwork prior to 2006, S. cerevisiae BTN1 had been implicat-
ed in the regulation of vacuolar (the yeast lysosome) and cellular pH,
basic amino acid homeostasis and nitric oxide production [330–336].
Sz. pombe btn1 has been reported to inﬂuence vacuolar pH and mor-
phology, cell polarity, cell wall deposition, heat tolerance and osmoreg-
ulation [337–339]. PEP4, the budding yeast orthologue of CLN10, is also
well-characterised, and known to mediate vacuolar protease matura-
tion and vacuolar morphology (reviewed in [340]). The ﬁssion yeast
CLN1 (ppt1) and CLN10 (sxa1) orthologues have received little attention
since their initial identiﬁcation and they are featured in only a small
number of early studies [341–343].
7.2. Modelling CLN3 disease in yeast
The now well-established yeast phenotypes associated with loss
of btn1 function have been exploited to probe the function of btn1
carrying disease-causing mutations. In a study by Haines et al. [344],
ﬁssion yeast expressing a range of such mutants was examined for
the rescue of a bank of marker phenotypes. Using this approach it
was indicated that a mutation, equivalent to the common intragenic
1 kb deletion in humans, retains some function and is able to rescue
defects in vacuolar size. Mutations in the luminal face of the protein,
in particular the amphipathic helix of the third luminal domain, had
the most severe effect upon function. Finally, the Btn1pE240K mutant,
which models a mutation (Glu295Lys) associated with a protracted
disease progression, was the only mutant able to rescue cell curving,
potentially indicating a signiﬁcant retention of function.
In another study that expanded upon known phenotypes of cells
lacking BTN1, Wolfe et al. [345] further probed the link between BTN1
and cellular pH in S. cerevisiae. The study indicated that BTN1p
underwent pH-dependent changes in localisation, glycosylation and ex-
pression levels. Expression of BTN1 was higher at pH 6.0 compared to
pH 4.0. The increase in BTN1p at pH 6.0 consisted exclusively of a
glycosylated formof the protein, and itwas suggested that this glycosyl-
ation was key to protein stability under these conditions. The change in
post-translational modiﬁcation was also accompanied by an alteration
in protein localisation. At pH 6.0, BTN1p co-localised with the vacuolar
V-ATPase at the vacuolar membrane. Yet, upon growth at pH 4.0,
BTN1p redistributed to unidentiﬁed cytosolic puncta. These ﬁndings
highlight the interplay between BTN1p, a protein known to be involved
in pH regulation, and environmental pH.
Further work has also explored this relationship [346]. Using
yeast two-hybrid protein interaction, co-immunoprecipitation and
co-localisation, BTN1pwas shown to interactwith SDO1p, an orthologue
of the protein mutated in Shwachman–Bodian–Diamond syndrome.
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V-ATPase activity. These phenotypes were exacerbated by BTN1 over-
expression or inhibition of proton transport, and could be recapitulated
under both these conditions in the presence of SDO1p. Based upon
these observations, it was suggested that BTN1p regulated V-ATPase ac-
tivity, negatively inﬂuencing the coupling of ATP hydrolysis to proton
pumping.More recentwork, however, indicated that therewas no direct
interaction between BTN1p and the V-ATPase [347]. Finally, due to the
role of SDO1p in ribosomal maturation, it was suggested that this path-
way was key to vacuolar function [346].
The experimental advantages inherent in the yeast model system
lend it to the analysis of global regulatory change, and the Sz. pombe
model for CLN3 disease has been used in this way to investigate the
metabolome of cells lacking btn1 [348]. Positive and negative changes
were observed in amino acid levels, in addition to a decrease in certain
nucleotides upon loss of btn1 function. The concentration of glucose in
spent growthmedia fromcells lacking btn1was also decreased compared
to wild-type control strains, suggesting an increased glycolytic ﬂux, and
markers for TCA cycle activitywere increased. Supplementationwith gly-
colytic substrates rescued the temperature-sensitive growth defect of
cells lacking btn1, suggesting that increased glycolysismay be an adaptive
change. Detailed analysis of these global metabolic changes may provide
new insights into the role of btn1 and, as a consequence, CLN3.
The emerging role of CLN3 and its orthologues inmembrane and pro-
tein trafﬁcking has received signiﬁcant attention in recent years. The link
was ﬁrst explored in mammalian systems, where it was demonstrated
that overexpression of CLN3 caused aggregation of Hook1, a protein
known to regulate endocytosis [349]. The S. cerevisiae orthologue of
Hook1, designated BTN2 due to its up-regulation in the absence of BTN1
[350], had already been implicated in vesicular targeting in budding
yeast [351], and was subsequently retrieved as an interacting partner of
the endocytic v-SNARE SNC1p [352]. The same study demonstrated that
BTN2p inﬂuences transport from the Golgi through the endosome, and
probably export from the late endosome. It was also suggested that
BTN2p may be necessary for the retrograde transport of certain cargoes
back to the Golgi.
A study in Sz. pombewas theﬁrst to explore such processes in a yeast
model for CLN3 disease [353]. In this yeast the loss of Btn1p was shown
to cause missorting and secretion of the vacuolar hydrolase carboxy-
peptidase Y (Cpy1p), a result of the retention of the Cpy1p receptor
Vps10p in the Golgi. Analysis of a number of double deletion strains,Table 6
Summary of yeast NCL models.
Human
gene
Yeast
species
Yeast
strain
Genetic mutation Molecular defect
Cathepsin
D, CLN10
S. cerevisiae PEP4Δ PEP4Δ::HIS3+
PEP4Δ::kanMX4
(Euroscarf deletion
library)
Complete deletion
Sz. pombe sxa1Δ sxa1Δ::ura4+ Complete deletion
Ppt1, CLN1 Sz. pombe pdf1S106A
pdf1D226A
pdf1Δ::his3+
pAAL-pdf1S106A
pdf1Δ::his3+
pAAL-pdf1D226A
Complete deletion of the pdf
consisting of ppt1 and the es
domain dolpp1. The expressi
plasmids pAAL-pdf1S106A and
pAAL-pdf1D226A restore dolpp
function but lack ppt1 functio
CLN3 S. cerevisiae BTN1Δ BTN1Δ::HIS3 Complete deletion
Sz. pombe btn1Δ btn1Δ::leu2
btn1Δ::ura4
Complete deletiondefective for vacuolar protein-sorting, demonstrated that Btn1p was
also involved in Vps10p-independent Cpy1p-sorting pathways.
Such observations would suggest that Btn1p has a direct inﬂuence
upon the secretory pathway. Indeed, the same study demonstrated
that Btn1p was located at the Golgi apparatus, and directly inﬂuenced
Golgi number, subcellular localisation andmorphology [353]. This inﬂu-
ence was later explored in the budding yeast model for CLN3 disease
[354]. Loss of BTN1 resulted in a similar phenotype to loss of BTN2,
preventing the retrieval of certain cargoes from the late endosome to
the Golgi. In addition, it was demonstrated that BTN1p localised to the
Golgi, which required transport from the late endosome. BTN1p also di-
rectly inﬂuenced the assembly of Golgi SNARE complexes, negatively
regulating the SNARE SED5p. This inﬂuence appeared to be due to the
phosphorylation of SED5p. In addition, BTN1p inﬂuenced Golgi mor-
phology, with the loss of BTN1p, and SED5p phosphorylation, causing
increased Golgi clustering. Finally, BTN1p was shown to inﬂuence
SED5pphosphorylation through the palmitoylated kinase YCK3p, possi-
bly by modulating its membrane anchoring.
Correct Golgi function is also vital to the metabolism and distribution
of membrane lipids. A recent study has explored the potential role of
BTN1 in phospholipid distribution in S. cerevisiae [347]. Loss of BTN1 led
to a decrease in the levels of phosphatidylethanolamine (PtdEtn) inmito-
chondrial and vacuolarmembranes. Deletion of BTN1 and PSD1, themito-
chondrial phosphatidylserine decarboxylase primarily responsible for
PtdEtn synthesis, caused a further decrease in PtdEtn levels, suggesting
that these two proteins may be acting at parallel pathways. A similar
but less pronounced effect was also seen with the Golgi/endosome asso-
ciated phosphatidylserine decarboxylase PSD2. A decreased rate of PtdEtn
transport from the ER to the mitochondria and vacuoles was also ob-
served in these double deletion strains. Ethanolamine supplementation
did not increase PtdEtn concentration and, at higher concentrations,
was toxic to cells lacking BTN1, suggesting impairment of ethanolamine
incorporation through the Kennedy pathway. Finally, it was suggested
that these alterations in phospholipid composition could account for
the impaired function of certain membrane bound proteins in cells lack-
ing BTN1, such as the vacuolar V-ATPase.
The regulatory link between BTN1 and BTN2 helped to identify
membrane and protein trafﬁcking as a potential function for BTN1.
This link could also prove fruitful in future analysis of BTN1 activity.
A number of recent studies have linked BTN2, and its newly identiﬁed
negative regulator BTN3, to the cellular stress response and prionPhenotype Reference
Altered vacuolar morphology, decreased
vacuolar protease maturation, protein turnover
and post-mitotic life span (increased apoptotic
and necrotic cell death)
[340,357]
Increased sensitivity to mating pheromone [341,342]
1 locus,
sential
on
1
n.
Increased sensitivity to vanidate and alkaline pH [343]
Reduced nitric oxide production, alteration in
vacuolar and cellular pH, basic amino acid
homeostasis, trafﬁcking and phospholipid
distribution
[330–336,345–347,354]
Alterations in vacuolar pH and morphology, cell
polarity, cell wall deposition, heat tolerance,
osmoregulation, trafﬁcking, Golgi size and
number, glycolytic ﬂux, amino acid and
nucleotide homeostasis
[337–339,348,353]
Fig. 3. Established roles for NCL gene orthologues in yeast. Budding yeast (A) BTN1 and
ﬁssion yeast (B) Btn1 are known to localise to the vacuolar (VAC) and Golgi (GA) mem-
branes. Likely from the vacuolar membrane, BTN1 is known to inﬂuence vacuolar pH
and Btn1 both vacuolar pH and morphology. The Golgi is the probable site from which
BTN1 affects membrane and protein trafﬁcking and Btn1 trafﬁcking in addition to Golgi
size and number. In budding yeast, BTN1 also regulates nitric oxide production, basic
amino acid homeostasis and phospholipid distribution, although the site at which these
occur is less apparent. Similarly, Btn1 also regulates septation, glycolysis, cell polarity,
cell wall biogenesis, osmoregulation and heat tolerance. Budding yeast PEP4 is a soluble
vacuolar hydrolase, which inﬂuences vacuolar morphology and directly regulates prote-
ase maturation. The PEP4 propeptide also has an anti-necrotic effect, causing histone
hypoacetylation in the nucleus (NUC).
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neurodegeneration, and may prove important in BTN1 function.7.3. Modelling CLN10 disease in yeast
Neurodegeneration is often viewed as a shortening of the chrono-
logical, or post-mitotic, lifespan of a cell. Yeast is an ideal system for
the study of chronological ageing, as quiescence can be easily induced
by carbon or nitrogen limitation. This system has yielded some im-
portant insights into the role of PEP4, the S. cerevisiae orthologue of
CLN10. PEP4 is key to maintaining viability in quiescent culture [357].
In addition, PEP4 expression increased with chronological age, and a
loss of PEP4 was associated with an increase in the oxidative damage
of cellular protein. The role of PEP4 in the turnover of oxidised proteinwas also highlighted by its up-regulation in response to exogenous
oxidative insults.
The positive inﬂuence of PEP4 upon lifespan can be divided into two
processes. As discussed, the proteolytic turnover of damaged protein by
PEP4p promotes cell survival, delaying apoptotic cell death. However,
catalytically inactive PEP4p also improves survival in quiescent yeast
populations by delaying necrotic cell death [358]. This activity was con-
ferred by the inactive PEP4p pro-peptide, and correlated with histone
hypoacetylation, and the nuclear retention of pro-necrotic factors.
These observations could prove highly relevant to NCL, as oxidative
stress-induced cell death is often associated with neuronal loss.
7.4. Summary
The conservation of these NCL genes from yeast to humans sug-
gests a fundamental role in eukaryotic cell biology. The use of simple
unicellular systems such as yeast therefore represents a powerful tool
to investigate the basic cellular changes that occur upon loss of gene
function. This approach has already helped to assert a role for CLN3
in lysosomal homeostasis, protein trafﬁcking, phospholipid distribu-
tion and the regulation of metabolic processes, and has highlighted
the importance of CLN10 in post-mitotic survival (summarised in
Fig. 3). Given that much is still not known about the basic function
of these genes, or the consequences of their loss, yeast will continue
to provide a valuable model for the basic cell biology of NCL.
8. Concluding remarks
The range of model organisms used for NCL research is clearly pro-
viding a wealth of information about protein function/dysfunction and
pathomechanisms, as well as providing new candidate NCL genes and
in vivomethods for testing a range of experimental therapies. The stud-
ies presented highlight the advantages of each organism and how each
of these attributes can be exploited further in future research, providing
a powerful arsenal of complementary tools to aid the search for and
testing of NCL therapies.
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